ALXO Stock Forecast: ALX Oncology Holdings, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.02
+5.15% on the day

The median 12-month analyst price target for ALX Oncology Holdings, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$139.0M
Ticker Nerd rank
40/ 100
Median analyst target
$4.00
Analysts covering
7
Revenue$0.0
Operating income−$18.3M
Net income−$18.0M
Free cash flow−$16.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.6%
1M
−10.5%
YTD
−9.7%
1Y
−30.6%
From 52W high
−60.8%
From 52W low
+14.0%
$0.90
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores ALX Oncology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
40/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
66
Growth
65
Volatility
64
Momentum
53
Issuance
45
Quality
42
Revisions
22
Value
22

Accruals (66): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (22): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALXO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALXO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26ALXOHigh $6.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6
Buy
1
Hold
0
Sell
$4.00
Low
$4.00
Median
$6.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Mar 2026Wells FargoInitiatesOverweight$5.00
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
5 Feb 2026Piper SandlerMaintainsOverweight—
21 May 2025UBSMaintainsBuy—
9 May 2025HC Wainwright & Co.MaintainsBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025StifelMaintainsHold—
6 Mar 2025JefferiesUpgradeBuy—
6 Mar 2025Piper SandlerMaintainsOverweight—
27 Jan 2025UBSMaintainsBuy—
24 Jan 2025Cantor FitzgeraldReiteratesOverweight—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024JefferiesDowngradeHold—
18 Dec 2024Cantor FitzgeraldReiteratesOverweight—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024Cantor FitzgeraldReiteratesOverweight—
16 Aug 2024UBSMaintainsBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
12 Aug 2024Cantor FitzgeraldReiteratesOverweight—
9 Aug 2024StifelReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALXO.

Market Radar

This page is one stock. Monday covers all of them.

ALXO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALXO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, ALX Oncology Holdings, Inc. returned −30.6% against +9.2% for the S&P 500, dividends included.

ALXO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26ALXOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALXO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.2×

Cheaper than 67% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−94.4%

Higher than 14% of US stocks

Return on assets
−43.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ALX Oncology Holdings, Inc. has a market value of $139.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$80.9M.

  • Diluted earnings per share, trailing twelve months: −$1.13.

  • Free cash flow in the twelve months to 30 June 2026: −$71.0M.

  • Shares outstanding: 138.2M.

  • ALX Oncology Holdings, Inc. employs 49 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ALXO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALXOALX Oncology Holdings, Inc.$139.0M40
MGNXMacroGenics, Inc.$125.2M87
NRXPNRX Pharmaceuticals, Inc.$124.1M19
ENGNenGene Therapeutics, Inc.$124.0M21
CDXSCodexis, Inc.$123.7M40
ZNTLZentalis Pharmaceuticals, Inc.$128.8M45
FATEFate Therapeutics, Inc.$122.1M85

Take a look at ALXO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own ALX Oncology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ALXO

What is the ALXO stock price forecast for 2026-2027?

The median 12-month analyst price target for ALX Oncology Holdings, Inc. is $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALXO stock a buy right now?

Of the 7 analysts covering ALX Oncology Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ALX Oncology Holdings, Inc. 40 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALXO?

As at 18 Nov 2026, ALX Oncology Holdings, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (66 of 100).

Will ALXO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $4, and Ticker Nerd's factor model ranks ALX Oncology Holdings, Inc. 40 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALXO stock forecast for 2030?

No analyst covering ALX Oncology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALXO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has ALXO stock performed over the past year?

ALX Oncology Holdings, Inc. returned -30.6% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ALX Oncology Holdings, Inc. do?

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications.

Company

About ALX Oncology Holdings, Inc.

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications. The company’s pipeline also includes ALX2004, an epidermal growth factor receptor-targeted antibody-drug conjugate under development for EGFR-expressing tumors. ALX Oncology’s work centers on protein engineering, combination therapy research, and clinical studies aimed at addressing difficult-to-treat cancers. Based in South San Francisco, California, the company operates within the broader oncology drug development market and collaborates with clinical trial sites and research partners to advance its product candidates.

CEO Mr. Jason W. Lettmann · 49 employees · United States · https://www.alxoncology.com